Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Chapman, Richard H.; Benner, Joshua S.; Petrilla, Allison; Tierce, Jonothan C.; Collins, Stephen R.; Battleman, David; Schwartz, J. Sanford

doi:10.1001/archinte.165.10.1147

Cited by 453 publications

(315 citation statements)

References 27 publications

(43 reference statements)

Supporting

Mentioning

275

Contrasting

Unclassified

Order By: Relevance

“…Concurrent drug therapy may be another reason for nonadherence [6]. The total number of drugs prescribed was reported to be inconsistently associated with refill compliance [31].…”

Section: Discussionmentioning

confidence: 99%

Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study

Shin

Park

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…Concurrent drug therapy may be another reason for nonadherence [6]. The total number of drugs prescribed was reported to be inconsistently associated with refill compliance [31].…”

Section: Discussionmentioning

confidence: 99%

Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study

Shin

Park

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…3 Most patients with hypertension have poorly controlled blood pressure (BP), and AAs are disproportionately represented among this group, 4 with a higher prevalence of diastolic hypertension in younger, Black populations compared to the mostly systolic hypertension seen in the elderly. 5 Clinician failure to aggressively manage hypertension (ie, clinical inertia) is an issue, 6 but even with adequate management, 43%-78% of patients fail to adhere to recommended therapies, [7][8][9] and AAs may be less likely to adhere to prescribed hypertension therapies than Whites. 10,11 There are likely multiple causal pathways to these disparities in adherence and BP outcomes, 12 suggesting several approaches to their reduction.…”

Section: Introductionmentioning

confidence: 99%

A Brief, Multifaceted, Generic Intervention to Improve Blood Pressure Control and Reduce Disparities Had Little Effect

et al. 2016

View full text Add to dashboard Cite

Results: Clinician counseling improved most at R+T. BP improved overall; R+T had a small but significantly greater reduction in diastolic BP (DBP; -1.7 mm Hg). White patients at RO experienced greater overall improvements in BP control. Site and race disparities trends suggested that disparities decreased at R+T, either stayed the same or decreased at Control; and stayed the same or increased at RO. Conclusions:More substantial or racial/ ethnically tailored interventions are needed.

show abstract

“…Several studies have characterized the problem of statin discontinuation by identifying subgroups of patients who are at high risk for discontinuing treatment 14, 19, 20, 21, 22. Few studies have described opportunities to re‐initiate statins.…”

Section: Discussionmentioning

confidence: 99%

Healthcare Utilization and Statin Re‐Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction

Booth

Colantonio

Rosenson

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundContact with the healthcare system represents an opportunity for individuals who discontinue statins to re‐initiate treatment. To help identify opportunities for healthcare providers to emphasize the risk‐lowering benefits accrued through restarting statins, we determined the types of healthcare utilization associated with statin re‐initiation among patients with history of a myocardial infarction.Methods and ResultsMedicare beneficiaries with a statin pharmacy fill claim within 30 days of hospital discharge for a myocardial infarction in 2007 to 2012 (n=158 795) were followed for 182 days postdischarge to identify treatment discontinuation, defined as 60 continuous days without statins (n=24 461). Re‐initiation was defined as a statin fill within 365 days of the discontinuation date (n=13 136). Using a case‐crossover study design and each beneficiary as their own control, healthcare utilization during 0 to 14 days before statin re‐initiation (case period) was compared with healthcare utilization 30 to 44 days before statin re‐initiation (control period). The mean age of beneficiaries was 75.4 years; 52.8% were women and 81.9% were white. For routine healthcare utilization, the odds ratio (95% confidence interval) for statin re‐initiation associated with lipid panel testing was 2.65 (1.93–3.65), outpatient primary care was 1.31 (1.23–1.40), and outpatient cardiologist care was 1.38 (1.28–1.50). For acute healthcare utilization, the odds ratio (95% confidence interval) for statin re‐initiation associated with emergency department visits was 1.77 (1.31–2.40), coronary heart disease (CHD) hospitalizations was 3.16 (2.41–4.14) and non–coronary heart disease hospitalizations was 1.73 (1.49–2.01).ConclusionsThe weaker association of routine versus acute healthcare utilization with statin re‐initiation suggests missed opportunities to reinforce the importance of statin therapy for secondary prevention.

show abstract

Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy

Abstract: Adherence with concomitant AH and LL therapy is poor, with only 1 in 3 patients adherent with both medications at 6 months. Physicians may be able to significantly improve adherence by initiating AH and LL therapy concomitantly and by reducing pill burden.

Cited by 453 publications

References 27 publications

Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study

Antihypertensive medication adherence in cancer survivors and its affecting factors: results of a Korean population-based study

A Brief, Multifaceted, Generic Intervention to Improve Blood Pressure Control and Reduce Disparities Had Little Effect

Healthcare Utilization and Statin Re‐Initiation Among Medicare Beneficiaries With a History of Myocardial Infarction

Contact Info

Product

Resources

About